ASH 2016 - Roundup
Chlorambucil plus Rituximab as Front-Line Therapy for Elderly and/or Unfit CLL Patients. Long-Term Follow-Up and Correlation with Biologic-Based Risk Stratification
Treatment of elderly and/or unfit chronic lymphocytic leukemia (CLL) patients with chlorambucil plus rituximab was associated with low toxicity, a high overall response rate, and durable progression-free survival, suggesting that in low-risk unfit patients, this combination may be an optimal therapeutic option taking into consideration safety, efficacy, and cost.
Healthcare utilization of elderly chronic lymphocytic leukemia (CLL) patients who remain on bendamustine-rituximab (BR) is significantly lower than patients who remain on fludarabine, cyclophosphamide, and rituximab (FCR), with FCR-treated patients experiencing significantly more days of hospitalization, outpatient visits, and emergency department visits than BR-treated patients.
Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma
In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Changing Demographics and Treatment Patterns in Patients in the United States with Chronic Lymphocytic Leukemia in the First-Line Setting as Assessed Using a Novel Electronic Health Record Database
Using a novel electronic health record database that included nearly 800 chronic lymphocytic leukemia patients, recent treatment patterns in the United States showed a decline in the use of fludarabine-, bendamustine-, and rituximab-containing regimens and a significant increase in the use of obinutuzumab and ibrutinib, either as monotherapy or in combination regimens.
Daratumumab Prolongs Survival Compared with Standard of Care in Patients with Heavily Pretreated and Highly Refractory Multiple Myeloma
Conference Correspondent - ASH 2016 - Multiple Myeloma, ASH 2016 - Roundup, Conference Correspondent
Compared with standard-of-care therapies delivered in a real-world setting, daratumumab monotherapy extends overall survival in patients with heavily pretreated and highly refractory multiple myeloma.
Results 1 - 5 of 5